| (Original Signature of Member)   |
|--|
| 118TH CONGRESS H.R.  |
| To authorize United States participation in the Davos Alzheimer's Collaborative. |
|  |
| IN THE HOUSE OF REPRESENTATIVES  |
| Mr. Bera introduced the following bill; which was referred to the Committee on   |
| A BILL   |
| To authorize United States participation in the Davos Alzheimer's Collaborative. |
| 1 Be it enacted by the Senate and House of Representa-                           |
| 2 tives of the United States of America in Congress assembled,                   |
| 3 SECTION 1. SHORT TITLE.  |
| 4 This Act may be cited as the "Global Alzheimer's Ini-                          |
| 5 tiative Now Act".  |
| 6 SEC. 2. FINDINGS.  |
| 7 Congress finds the following:  |
| 8 (1) Alzheimer's disease and dementia currently                                 |

afflicts nearly 60 million people across the globe, a

9

| 1  | number that is projected to jump to more than 150   |
|----|---|
| 2  | million by 2050.                                    |
| 3  | (2) There are now more global cases of Alz-         |
| 4  | heimer's disease and dementia than cancer and HIV   |
| 5  | combined, with 39 million diagnosed cases of HIV/   |
| 6  | AIDS and 20 million cases of cancer in 2022.        |
| 7  | (3) The pace of populations aging will challenge    |
| 8  | countries' sovereign funds and health and social    |
| 9  | safety systems.                                     |
| 10 | (4) By 2050, the world's population of people       |
| 11 | aged 60 years and older will double to 1.6 billion  |
| 12 | and reach a proportion of 22 percent of the world's |
| 13 | population. While the number of persons aged 80 or  |
| 14 | older is expected to triple by 2050.                |
| 15 | (5) The old-age dependency ratio, expressing        |
| 16 | the relative size of the older population compared  |
| 17 | with the working-age population, is projected to    |
| 18 | more than double by 2075 in the majority of the     |
| 19 | world. Rising dependency ratios will result in in-  |
| 20 | creasing pressures on old-age support systems, with |
| 21 | fewer people of working age for each older person.  |
| 22 | (6) The prevalence of Alzheimer's disease and       |
| 23 | dementia is growing most rapidly in low- and mid-   |
| 24 | dle-income countries, which comprise more than 70   |

| 1  | percent of the world's Alzheimer's disease and de-    |
|----|---|
| 2  | mentia cases.   |
| 3  | (7) Every year, Alzheimer's disease and demen-        |
| 4  | tia costs the global economy more than \$1.3 trillion |
| 5  | and this is doubling every decade.                    |
| 6  | (8) By 2050, the number of Americans living           |
| 7  | with Alzheimer's disease and dementia is expected to  |
| 8  | reach 12.7 million, bringing the total cost to nearly |
| 9  | \$1 trillion each year.                               |
| 10 | (9) Women are disproportionately affected by          |
| 11 | Alzheimer's disease and dementia, both directly and   |
| 12 | indirectly. Women experience higher disability-ad-    |
| 13 | justed life years and mortality due to Alzheimer's    |
| 14 | disease and dementia, but also provide 70 percent of  |
| 15 | care hours for people living with Alzheimer's disease |
| 16 | and dementia.   |
| 17 | (10) The Davos Alzheimer's Collaborative              |
| 18 | (DAC) is a public-private-patient venture, launched   |
| 19 | in 2021, that is transforming Alzheimer's disease     |
| 20 | and dementia research, prevention, and care in low-   |
| 21 | income, middle-income, and high-income settings       |
| 22 | globally.   |
| 23 | (11) DAC seeks to raise and deploy over \$700         |
| 24 | million over 6 years to accelerate innovation in drug |
| 25 | development and transform the way healthcare sys-     |

| 1  | tems prevent, diagnose, and treat Alzheimer's dis-     |
|----|--|
| 2  | ease and dementia for all people in all places.        |
| 3  | (12) In 2023, DAC supported 19 healthcare              |
| 4  | systems in 12 countries, including the United States.  |
| 5  | (13) The United States Government is the larg-         |
| 6  | est funder of global health programs, with approxi-    |
| 7  | mately \$12 billion in annual funding for programs     |
| 8  | that cover the full range of global health challenges. |
| 9  | (14) USAID and the Department of State are             |
| 10 | lead funders of multilateral health initiatives, such  |
| 11 | as Gavi, the Vaccine Alliance, the Global Fund to      |
| 12 | Fight AIDS, TB and Malaria, the Coalition for Epi-     |
| 13 | demic Preparedness Innovations, and the Inter-         |
| 14 | national AIDS Vaccine Initiative.                      |
| 15 | SEC. 3. STATEMENT OF POLICY.                           |
| 16 | It shall be the policy of the United States—           |
| 17 | (1) to lead global cooperative efforts to combat       |
| 18 | Alzheimer's disease and dementia, including in coun-   |
| 19 | tries with low-income economies and countries with     |
| 20 | middle-income economies (as such terms are defined     |
| 21 | by the World Bank) that represent the majority of      |
| 22 | future cases; and                                      |
| 23 | (2) to lead multilateral health initiatives, in-       |
|    |  |

| 1  | (A) to develop diagnostics and treatments                  |
|----|--|
| 2  | for diverse populations in the United States and           |
| 3  | across the globe;  |
| 4  | (B) to promote international development                   |
| 5  | cooperation; and   |
| 6  | (C) to provide substantial leverage and                    |
| 7  | burden sharing for United States investments.              |
| 8  | SEC. 4. AUTHORIZATION FOR UNITED STATES PARTICIPA-         |
| 9  | TION IN THE DAVOS ALZHEIMER'S COLLABO-                     |
| 10 | RATIVE.  |
| 11 | (a) In General.—The United States is hereby au-            |
| 12 | thorized to participate in, and contribute to, the Davos   |
| 13 | Alzheimer's Collaborative (DAC) in order to advance        |
| 14 | international efforts to prevent, diagnose, and treat Alz- |
| 15 | heimer's disease and dementia.                             |
| 16 | (b) Designee.—   |
| 17 | (1) In general.—The President is authorized                |
| 18 | to designate an employee of the relevant Federal de-       |
| 19 | partment or agency providing the majority of United        |
| 20 | States contributions to DAC to serve on the Advi-          |
| 21 | sory Council of DAC and, if nominated, on the              |
| 22 | Board of Directors of DAC, as a representative of          |
| 23 | the United States.   |
| 24 | (2) QUALIFICATIONS.—The individual to be                   |
| 25 | designated pursuant to paragraph (1) should dem-           |

| 1  | onstrate knowledge and experience in the fields of   |
|----|--|
| 2  | development and public health.                       |
| 3  | (3) Cooperation.—In carrying out this sec-           |
| 4  | tion, the individual designated pursuant to para-    |
| 5  | graph (1) shall coordinate with the USAID Adminis-   |
| 6  | trator, the Secretary of State, and the Secretary of |
| 7  | Health and Human Services to promote alignment,      |
| 8  | as appropriate, between DAC and United States        |
| 9  | global health and Alzheimer's disease and dementia   |
| 10 | research and development programs.                   |
| 11 | (c) United States Contributions.—                    |
| 12 | (1) In general.—Amounts authorized to be             |
| 13 | appropriated and made available to carry out chap-   |
| 14 | ters 1 and 10 of part I and chapter 4 of part II of  |
| 15 | the Foreign Assistance Act of 1961 (22 U.S.C. 2151   |
| 16 | et seq.) are authorized to be made available for     |
| 17 | United States contributions to DAC.                  |
| 18 | (2) Matching requirement.—Amounts made               |
| 19 | available under paragraph (1) may be obligated and   |
| 20 | expended only to the extent that DAC secures fund-   |
| 21 | ing from sources other than the United States. At    |
| 22 | any time during fiscal years 2025 through 2029, no   |
| 23 | United States contribution to DAC may cause the      |
| 24 | total amount of United States Government contribu-   |
| 25 | tions to DAC to exceed 33 percent of the total       |

| 1  | amount of funds contributed to the DAC from all             |
|----|---|
| 2  | sources.  |
| 3  | (d) Report.—Not later than 180 days after the date          |
| 4  | of the enactment of this Act, and on an annual basis there- |
| 5  | after, the President shall submit to the appropriate con-   |
| 6  | gressional committees a report that includes the following: |
| 7  | (1) A description of any planned financial con-             |
| 8  | tributions from the United States Government to             |
| 9  | DAC.  |
| 10 | (2) The manner and extent to which the United               |
| 11 | States will participate in the governance of DAC.           |
| 12 | (3) A summary of private and governmental                   |
| 13 | contributions to DAC.                                       |
| 14 | (4) A description of how participation in DAC               |
| 15 | supports relevant United States Government strate-          |
| 16 | gies and programs to combat Alzheimer's disease             |
| 17 | and dementia and to promote global health.                  |
| 18 | (e) Definition.—In subsection (d), the term "ap-            |
| 19 | propriate congressional committees" means—                  |
| 20 | (1) the Committee on Foreign Affairs and Com-               |
| 21 | mittee on Appropriations of the House of Represent-         |
| 22 | atives; and   |
| 23 | (2) the Committee on Foreign Relations and                  |
| 24 | the Committee on Appropriations of the Senate.              |